Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
2777 participants
OBSERVATIONAL
2016-08-31
2021-07-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study design includes three study arms:
1. ARENA Intervention: This project will examine the effectiveness of population education.
2. ARENA Medication: The aim is to examine the patient's adherence and to analyze whether there are any complications.
3. ARENA Migration: ARENA migration aims to examine whether a targeted population education can improve the care of people with a Turkish migration background.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Affera Global Registry
NCT06026345
ABLATOR Ablation Observational Registry
NCT02344173
Atrial Fibrillation Ablation Registry
NCT03075930
Atrial Fibrillation General Registry
NCT02518984
Risk Profile for Patients With Atrial Fibrillation
NCT01510210
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study design includes three study arms:
1. ARENA Intervention:
This project will examine the effectiveness of population education and other measures to provide care for patients with atrial fibrillation.
In the end of the control phase (1 year recruitment of approximately 10,000 patients), there will be a wide publicity, informing about the disease.
2. ARENA Medication:
ARENA records the patient's complete medication at all survey times (up to two weeks after recruitment and follow up). This allows an accurate assessment of interactions between individual substances.
In addition, attempts are being made to determine drug concentrations of anticoagulants directly by the blood of the patient. Therefore, patients are provided with kits, which they can use to apply a drop of blood from your fingertip to a filter paper. The aim is to examine the patient's adherence and to analyze whether there are any complications.
3. ARENA Migration:
The Metropolregion Rhein-Neckar is characterized by a high proportion of people with a Turkish migration background. ARENA migration aims to examine whether a targeted population education can improve the care of this patient group.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Atiral fibrilation
* 18 years or older
Exclusion Criteria
18 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Stiftung Institut fuer Herzinfarktforschung
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Martin Borggrefe, Prof. Dr.
Role: PRINCIPAL_INVESTIGATOR
Universitätsmedizin Mannheim
Walter E. Haefeli, Prof. Dr.
Role: STUDY_CHAIR
University Hospital Heidelberg
Ömer Sanatci, Dr. med.
Role: STUDY_CHAIR
Praxis Merz Sanatci
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Universitätsklinikum Heidelberg
Heidelberg, Baden-Wurttemberg, Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Brockmuller C, Meid AD, Senges J, Hochadel M, Haefeli WE, Stoll F. Phenotypes of Patients with Direct Oral Anticoagulant (DOAC) Underdosing in Atrial Fibrillation: Results from the ARENA Registry. Clin Drug Investig. 2025 Jan;45(1):29-43. doi: 10.1007/s40261-024-01411-w. Epub 2024 Dec 12.
Zylla MM, Ozdemir B, Hochadel M, Zeymer U, Akin I, Grau A, Schneider S, Alonso A, Waldecker B, Suselbeck T, Schwacke H, Haass M, Zahn R, Borggrefe M, Senges J, Frey N, Thomas D. Community-based analysis of stroke prevention and effect of public interventions in atrial fibrillation: results from the ARENA project. Clin Res Cardiol. 2025 Jan;114(1):138-149. doi: 10.1007/s00392-024-02510-6. Epub 2024 Aug 8.
Sadlonova M, Salzmann S, Senges J, Celano CM, Huffman JC, Borggrefe M, Akin I, Thomas D, Schwarzbach CJ, Kleemann T, Schneider S, Hochadel M, Suselbeck T, Schwacke H, Alonso A, Haass M, Ladwig KH, Herrmann-Lingen C. Generalized anxiety is a predictor of impaired quality of life in patients with atrial fibrillation: Findings from the prospective observational ARENA study. J Psychosom Res. 2024 Jan;176:111542. doi: 10.1016/j.jpsychores.2023.111542. Epub 2023 Nov 8.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ARENA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.